|
1
|
Ru W, Zhang X, Yue B, Qi A, Shen X, Huang
Y, Lan X, Lei C and Chen H: Insight into m6A methylation
from occurrence to functions. Open Biol. 10:2000912020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang Q, Chen C, Ding Q, Zhao Y, Wang Z,
Chen J, Jiang Z, Zhang Y, Xu G, Zhang J, et al: METTL3-mediated
m6A modification of HDGF mRNA promotes gastric cancer
progression and has prognostic significance. Gut. 69:1193–1205.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu
HC, Yuan WB, Lu JC, Zhou ZJ, Lu Q, et al: METTL3 promote tumor
proliferation of bladder cancer by accelerating pri-miR221/222
maturation in m6A-dependent manner. Mol Cancer. 18:1102019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chu S and Li Y, Wu B, Rong G, Hou Q, Zhou
Q, Du D and Li Y: METTL3 promotes the growth and invasion of
melanoma cells by regulating the lncRNA SNHG3/miR-330-5p axis. Cell
Transplant. 32:96368972311883002023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH,
Wang F, Wang TT, Xu QG, Zhou WP and Sun SH: METTL14 suppresses the
metastatic potential of hepatocellular carcinoma by modulating
N6-methyladenosine-dependent primary MicroRNA
processing. Hepatology. 65:529–543. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang X, Zhang X, Liu T, Zhang Z, Piao C
and Ning H: METTL14 promotes migration and invasion of choroidal
melanoma by targeting RUNX2 mRNA via m6A modification. J Cell Mol
Med. 26:5602–5613. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhuang A, Gu X, Ge T, Wang S, Ge S, Chai
P, Jia R and Fan X: Targeting histone deacetylase suppresses tumor
growth through eliciting METTL14-modified m6 A RNA
methylation in ocular melanoma. Cancer Commun (Lond). 43:1185–1206.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Popović AM, Huđek Turković A, Žuna K,
Bačun-Družina V, Rubelj I and Matovinović M: FTO gene polymorphisms
at the crossroads of metabolic pathways of obesity and epigenetic
influences. Food Technol Biotechnol. 61:14–26. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang M, Guo J, Liu L, Jin H, Chen X and
Zou J: m6A demethylase FTO and osteoporosis: Potential therapeutic
interventions. Front Cell Dev Biol. 11:12754752023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang S, Wei J, Cui YH, Park G, Shah P,
Deng Y, Aplin AE, Lu Z, Hwang S, He C and He YY: m6A mRNA
demethylase FTO regulates melanoma tumorigenicity and response to
anti-PD-1 blockade. Nat Commun. 10:27822019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye J, Chen X, Jiang X, Dong Z, Hu S and
Xiao M: RNA demethylase ALKBH5 regulates hypopharyngeal squamous
cell carcinoma ferroptosis by posttranscriptionally activating
NFE2L2/NRF2 in an m6 A-IGF2BP2-dependent manner. J Clin
Lab Anal. 36:e245142022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qu J, Yan H, Hou Y, Cao W, Liu Y, Zhang E,
He J and Cai Z: RNA demethylase ALKBH5 in cancer: From mechanisms
to therapeutic potential. J Hematol Oncol. 15:82022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
You Y, Wen D, Zeng L, Lu J, Xiao X, Chen
Y, Song H and Liu Z: ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage
infiltration and promotes hepatocellular carcinoma progression. Int
J Biol Sci. 18:5001–5018. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang H, Zhao S, Liu H, Liu Y, Zhang Z,
Zhou Z, Wang P, Qi S and Xie J: ALKBH5 facilitates the progression
of skin cutaneous melanoma via mediating ABCA1 demethylation and
modulating autophagy in an m6A-dependent manner. Int J
Biol Sci. 20:1729–1743. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schadendorf D, van Akkooi ACJ, Berking C,
Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A and Ugurel
S: Melanoma. Lancet. 392:971–984. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hao L, Yin J, Yang H, Li C, Zhu L, Liu L
and Zhong J: ALKBH5-mediated m6A demethylation of FOXM1
mRNA promotes progression of uveal melanoma. Aging (Albany NY).
13:4045–4062. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jia R, Chai P, Wang S, Sun B, Xu Y, Yang
Y, Ge S, Jia R, Yang YG and Fan X: m6A modification
suppresses ocular melanoma through modulating HINT2 mRNA
translation. Mol Cancer. 18:1612019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
O'Neill CH and Scoggins CR: Melanoma. J
Surg Oncol. 120:873–881. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Garbe C, Amaral T, Peris K, Hauschild A,
Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol
V, Dréno B, et al: European consensus-based interdisciplinary
guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J
Cancer. 170:236–255. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rietschel P, Panageas KS, Hanlon C, Patel
A, Abramson DH and Chapman PB: Variates of survival in metastatic
uveal melanoma. J Clin Oncol. 23:8076–8080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goldemberg DC, de Melo AC, de Melo Pino LC
and Thuler LCS: Epidemiological profile of mucosal melanoma in
Brazil. Sci Rep. 10:5052020. View Article : Google Scholar
|
|
22
|
Tsao H, Chin L, Garraway LA and Fisher DE:
Melanoma: From mutations to medicine. Genes Dev. 26:1131–1155.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Houben R, Hesbacher S, Schmid CP, Kauczok
CS, Flohr U, Haferkamp S, Müller CS, Schrama D, Wischhusen J and
Becker JC: High-level expression of wild-type p53 in melanoma cells
is frequently associated with inactivity in p53 reporter gene
assays. PLoS One. 6:e220962011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nikolaou V, Kang X, Stratigos A, Gogas H,
Latorre MC, Gabree M, Plaka M, Njauw CN, Kypreou K, Mirmigi I, et
al: Comprehensive mutational analysis of CDKN2A and CDK4 in Greek
patients with cutaneous melanoma. Br J Dermatol. 165:1219–1222.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boussadia Z, Gambardella AR, Mattei F and
Parolini I: Acidic and hypoxic microenvironment in melanoma: Impact
of tumour exosomes on disease progression. Cells. 10:33112021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen J, Ye M, Bai J, Hu C, Lu F, Gu D, Yu
P and Tang Q: Novel insights into the interplay between m6A
modification and programmed cell death in cancer. Int J Biol Sci.
19:1748–1763. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheung JCT, Deng G, Wong N, Dong Y and Ng
SSM: More than a duologue: In-depth insights into
epitranscriptomics and ferroptosis. Front Cell Dev Biol.
10:9826062022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Canaani D, Kahana C, Lavi S and Groner Y:
Identification and mapping of N6-methyladenosine containing
sequences in simian virus 40 RNA. Nucleic Acids Res. 6:2879–2899.
1979. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He L, Li H, Wu A, Peng Y, Shu G and Yin G:
Functions of N6-methyladenosine and its role in cancer. Mol Cancer.
18:1762019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zaccara S, Ries RJ and Jaffrey SR:
Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell
Biol. 20:608–624. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He PC and He C: m6 A RNA
methylation: From mechanisms to therapeutic potential. EMBO J.
40:e1059772021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang X, Liu B, Nie Z, Duan L, Xiong Q,
Jin Z, Yang C and Chen Y: The role of m6A modification in the
biological functions and diseases. Signal Transduct Target Ther.
6:742021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
De Jesus DF, Zhang Z, Kahraman S, Brown
NK, Chen M, Hu J, Gupta MK, He C and Kulkarni RN: m6A
mRNA methylation regulates human β-cell biology in physiological
states and in type 2 diabetes. Nat Metab. 1:765–774. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo J, Ren W, Li A, Ding Y, Guo W, Su D,
Hu C, Xu K, Chen H, Xu X, et al: Fat mass and obesity-associated
gene enhances oxidative stress and lipogenesis in nonalcoholic
fatty liver disease. Dig Dis Sci. 58:1004–1009. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin Y, Shen X, Ke Y, Lan C, Chen X, Liang
B, Zhang Y and Yan S: Activation of osteoblast ferroptosis via the
METTL3/ASK1-p38 signaling pathway in high glucose and high fat
(HGHF)-induced diabetic bone loss. FASEB J. 36:e221472022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Geula S, Moshitch-Moshkovitz S,
Dominissini D, Mansour AA, Kol N, Salmon-Divon M, Hershkovitz V,
Peer E, Mor N, Manor YS, et al: Stem cells. m6A mRNA methylation
facilitates resolution of naïve pluripotency toward
differentiation. Science. 347:1002–1006. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang
L, Jia G, Yu M, Lu Z, Deng X, et al: A METTL3-METTL14 complex
mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem
Biol. 10:93–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ping XL, Sun BF, Wang L, Xiao W, Yang X,
Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS, et al: Mammalian WTAP is
a regulatory subunit of the RNA N6-methyladenosine
methyltransferase. Cell Res. 24:177–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oerum S, Meynier V, Catala M and Tisné C:
A comprehensive review of m6A/m6Am RNA methyltransferase
structures. Nucleic Acids Res. 49:7239–7255. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang P, Doxtader KA and Nam Y: Structural
basis for cooperative function of Mettl3 and Mettl14
methyltransferases. Mol Cell. 63:306–317. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu X, Du Y, Huang Z, Qin H, Chen J and
Zhao Y: Insights into roles of METTL14 in tumors. Cell Prolif.
55:e131682022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu R, Jiang D, Wang Y and Wang X: N
(6)-Methyladenosine (m(6)A) methylation in mRNA with A dynamic and
reversible epigenetic modification. Mol Biotechnol. 58:450–459.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mathoux J, Henshall DC and Brennan GP:
Regulatory mechanisms of the RNA modification m6A and
significance in brain function in health and disease. Front Cell
Neurosci. 15:6719322021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Meyer KD and Jaffrey SR: Rethinking
m6A readers, writers, and erasers. Annu Rev Cell Dev
Biol. 33:319–342. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ju G, Lei J, Cai S, Liu S, Yin X and Peng
C: The emerging, multifaceted role of WTAP in cancer and cancer
therapeutics. Cancers (Basel). 15:30532023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Huang Q, Mo J, Liao Z, Chen X and Zhang B:
The RNA m6A writer WTAP in diseases: Structure, roles,
and mechanisms. Cell Death Dis. 13:8522022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li Y, Su R, Deng X, Chen Y and Chen J: FTO
in cancer: Functions, molecular mechanisms, and therapeutic
implications. Trends Cancer. 8:598–614. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Han Z, Niu T, Chang J, Lei X, Zhao M, Wang
Q, Cheng W, Wang J, Feng Y and Chai J: Crystal structure of the FTO
protein reveals basis for its substrate specificity. Nature.
464:1205–1209. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
You Y, Fu Y, Huang M, Shen D, Zhao B, Liu
H, Zheng Y and Huang L: Recent advances of m6A demethylases
inhibitors and their biological functions in human diseases. Int J
Mol Sci. 23:58152022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xiao D, Fang TX, Lei Y, Xiao SJ, Xia JW,
Lin TY, Li YL, Zhai JX, Li XY, Huang SH, et al: m6A
demethylase ALKBH5 suppression contributes to esophageal squamous
cell carcinoma progression. Aging (Albany NY). 13:21497–21512.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xu C, Liu K, Tempel W, Demetriades M, Aik
W, Schofield CJ and Min J: Structures of human ALKBH5 reveal a
unique binding mode for single-stranded RNA substrates. J Biol
Chem. 289:17299–17311. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang Y, Lu G, Xue X, Xie M, Wang Z, Ma Z,
Feng Y, Shao C, Duan H, Pan M, et al: Characterization and
validation of a ferroptosis-related LncRNA signature as a novel
prognostic model for lung adenocarcinoma in tumor microenvironment.
Front Immunol. 13:9037582022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tang Z, Huang X, Mei H and Zheng Z:
Silencing of METTL3 suppressed ferroptosis of myocardial cells by
m6A modification of SLC7A11 in a YTHDF2 manner. J Bioenerg
Biomembr. 56:149–157. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang S, Wang Y, Li Q, Zeng K, Li X and
Feng X: RUNX1-IT1 favors breast cancer carcinogenesis through
regulation of IGF2BP1/GPX4 axis. Discov Oncol. 14:422023.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bell JL, Wächter K, Mühleck B, Pazaitis N,
Köhn M, Lederer M and Hüttelmaier S: Insulin-like growth factor 2
mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of
cancer progression? Cell Mol Life Sci. 70:2657–2675. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lu Z, Yang H, Shao Y, Sun W, Jiang Y and
Li J: IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular
carcinoma. Biochem Biophys Res Commun. 627:103–110. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wu H, Li F and Zhu R: miR-338-5p inhibits
cell growth and migration via inhibition of the METTL3/m6A/c-Myc
pathway in lung cancer. Acta Biochim Biophys Sin (Shanghai).
53:304–316. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wen J, Zhang G, Meng Y, Zhang L, Jiang M
and Yu Z: RNA m6A methyltransferase METTL3 promotes
colorectal cancer cell proliferation and invasion by regulating
Snail expression. Oncol Lett. 22:7112021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shen S, Jin H, Zhang X, Zhang Y, Li X, Yan
W, Xie S, Yu B, Hu J, Liu H, et al: LINC00426, a novel
m6A-regulated long non-coding RNA, induces EMT in
cervical cancer by binding to ZEB1. Cell Signal. 109:1107882023.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W,
Guo W, Wu X, Pu C, Hu X, et al: METTL3/IGF2BP3 axis inhibits tumor
immune surveillance by upregulating N6-methyladenosine
modification of PD-L1 mRNA in breast cancer. Mol Cancer. 21:602022.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hu C, Liu J, Li Y, Jiang W, Ji D, Liu W
and Ma T: Multifaceted Roles of the N6-methyladenosine
RNA methyltransferase METTL3 in cancer and immune microenvironment.
Biomolecules. 12:10422022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liao Y, Han P, Zhang Y and Ni B:
Physio-pathological effects of m6A modification and its potential
contribution to melanoma. Clin Transl Oncol. 23:2269–2279. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yue B, Song C, Yang L, Cui R, Cheng X,
Zhang Z and Zhao G: METTL3-mediated N6-methyladenosine modification
is critical for epithelial-mesenchymal transition and metastasis of
gastric cancer. Mol Cancer. 18:1422019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Xu QC, Tien YC, Shi YH, Chen S, Zhu YQ,
Huang XT, Huang CS, Zhao W and Yin XY: METTL3 promotes intrahepatic
cholangiocarcinoma progression by regulating IFIT2 expression in an
m6A-YTHDF2-dependent manner. Oncogene. 41:1622–1633.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wang M, Liu J, Zhao Y, He R, Xu X, Guo X,
Li X, Xu S, Miao J, Guo J, et al: Upregulation of METTL14 mediates
the elevation of PERP mRNA N6 adenosine methylation
promoting the growth and metastasis of pancreatic cancer. Mol
Cancer. 19:1302020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yi D, Wang R, Shi X, Xu L, Yilihamu Y and
Sang J: METTL14 promotes the migration and invasion of breast
cancer cells by modulating N6-methyladenosine and hsa-miR-146a-5p
expression. Oncol Rep. 43:1375–1386. 2020.PubMed/NCBI
|
|
67
|
Xu D, Han S, Yue X, Xu X and Huang T:
METTL14 suppresses tumor stemness and metastasis of colon cancer
cells by modulating m6A-modified SCD1. Mol Biotechnol.
66:2095–2105. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Fan HN, Chen ZY, Chen XY, Chen M, Yi YC,
Zhu JS and Zhang J: METTL14-mediated m6A modification of
circORC5 suppresses gastric cancer progression by regulating
miR-30c-2-3p/AKT1S1 axis. Mol Cancer. 21:512022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yang X, Zhang S, He C, Xue P, Zhang L, He
Z, Zang L, Feng B, Sun J and Zheng M: METTL14 suppresses
proliferation and metastasis of colorectal cancer by
down-regulating oncogenic long non-coding RNA XIST. Mol Cancer.
19:462020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Liu W, Gao X, Chen X, Zhao N, Sun Y, Zou
Y, Guan Y, Yang L, Pei X, Wang G, et al: miR-139-5p loss-mediated
WTAP activation contributes to hepatocellular carcinoma progression
by promoting the epithelial to mesenchymal transition. Front Oncol.
11:6115442021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Schöller E, Weichmann F, Treiber T, Ringle
S, Treiber N, Flatley A, Feederle R, Bruckmann A and Meister G:
Interactions, localization, and phosphorylation of the
m6A generating METTL3-METTL14-WTAP complex. RNA.
24:499–512. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
He J, Li X, Lü M, Wang J, Tang J, Luo S
and Qian Y: ALKBH5 suppresses migration and invasion of human
trophoblast cells by inhibiting epithelial-mesenchymal transition.
Nan Fang Yi Ke Da Xue Xue Bao. 40:1720–1725. 2020.(In Chinese).
PubMed/NCBI
|
|
73
|
Zheng Z, Lin F, Zhao B, Chen G, Wei C,
Chen X, Nie R, Zhang R, Zhao Z, Zhou Z, et al: ALKBH5 suppresses
gastric cancer tumorigenesis and metastasis by inhibiting the
translation of uncapped WRAP53 RNA isoforms in an m6A-dependent
manner. Mol Cancer. 24:192025. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Tang W, Xu N, Zhou J, He Z, Lenahan C,
Wang C, Ji H, Liu B, Zou Y, Zeng H and Guo H: ALKBH5 promotes
PD-L1-mediated immune escape through m6A modification of ZDHHC3 in
glioma. Cell Death Discov. 8:4972022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Li Y, Gu J, Xu F, Zhu Q, Chen Y, Ge D and
Lu C: Molecular characterization, biological function, tumor
microenvironment association and clinical significance of m6A
regulators in lung adenocarcinoma. Brief Bioinform. 22:bbaa2252021.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Liu Y, Wang R, Zhang L, Li J, Lou K and
Shi B: The lipid metabolism gene FTO influences breast cancer cell
energy metabolism via the PI3K/AKT signaling pathway. Oncol Lett.
13:4685–4690. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Huang S, Wu Z, Cheng Y, Wei W and Hao L:
Insulin-like growth factor 2 mRNA binding protein 2 promotes
aerobic glycolysis and cell proliferation in pancreatic ductal
adenocarcinoma via stabilizing GLUT1 mRNA. Acta Biochim Biophys Sin
(Shanghai). 51:743–752. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tan B, Zhou K, Liu W, Prince E, Qing Y, Li
Y, Han L, Qin X, Su R, Pokharel SP, et al: RNA
N6-methyladenosine reader YTHDC1 is essential for
TGF-beta-mediated metastasis of triple negative breast cancer.
Theranostics. 12:5727–5743. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Cao D, Ge S and Li M: MiR-451a promotes
cell growth, migration and EMT in osteosarcoma by regulating
YTHDC1-mediated m6A methylation to activate the AKT/mTOR signaling
pathway. J Bone Oncol. 33:1004122022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yde SS, Sjoegren P, Heje M and Stolle LB:
Mucosal melanoma: A literature review. Curr Oncol Rep. 20:282018.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lee KA and Nathan P: Cutaneous melanoma-A
review of systemic therapies. Acta Derm Venereol. 100:adv001412020.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Dahal U, Le K and Gupta M: RNA m6A
methyltransferase METTL3 regulates invasiveness of melanoma cells
by matrix metallopeptidase 2. Melanoma Res. 29:382–389. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yue Z, Cao M, Hong A, Zhang Q, Zhang G,
Jin Z, Zhao L, Wang Q, Fang F, Wang Y and Sun J: m6A
methyltransferase METTL3 promotes the progression of primary acral
melanoma via mediating TXNDC5 methylation. Front Oncol.
11:7703252022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Feng ZY, Wang T, Su X and Guo S:
Identification of the m6A RNA methylation regulators WTAP as a
novel prognostic biomarker and genomic alterations in cutaneous
melanoma. Front Mol Biosci. 8:6652222021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Krishnamurthy N and Kurzrock R: Targeting
the Wnt/beta-catenin pathway in cancer: Update on effectors and
inhibitors. Cancer Treat Rev. 62:50–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Durante MA, Rodriguez DA, Kurtenbach S,
Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG,
Livingstone AS and Harbour JW: Single-cell analysis reveals new
evolutionary complexity in uveal melanoma. Nat Commun. 11:4962020.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Mehnert JM, Varga A, Brose MS, Aggarwal
RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA,
et al: Safety and antitumor activity of the anti-PD-1 antibody
pembrolizumab in patients with advanced, PD-L1-positive papillary
or follicular thyroid cancer. BMC Cancer. 19:1962019. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Bu X, Yao Y and Li X: Immune checkpoint
blockade in breast cancer therapy. Adv Exp Med Biol. 1026:383–402.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Kleffel S, Posch C, Barthel SR, Mueller H,
Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, et al:
Melanoma cell-intrinsic PD-1 receptor functions promote tumor
growth. Cell. 162:1242–1256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ma E, Li J, Shen C, Gu Y, Zhang X, Li L,
Zhao J and Wang Z: The m6A-related gene signature
stratifies poor prognosis patients and characterizes
immunosuppressive microenvironment in hepatocellular carcinoma.
Front Immunol. 14:12275932023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Shi S, Fan Z, Liu Y, Huang C and Zhou J:
Integration analysis of m6a related genes in skin cutaneous
melanoma and the biological function research of the SPRR1B. Front
Oncol. 11:7290452021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wu L, Hu X, Dai H, Chen K and Liu B:
Identification of an m6A regulators-mediated prognosis signature
for survival prediction and its relevance to immune infiltration in
melanoma. Front Cell Dev Biol. 9:7189122021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wu H, Xu H, Jia D, Li T and Xia L:
METTL3-induced UCK2 m6A hypermethylation promotes
melanoma cancer cell metastasis via the WNT/β-catenin pathway. Ann
Transl Med. 9:11552021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li N, Kang Y, Wang L, Huff S, Tang R, Hui
H, Agrawal K, Gonzalez GM, Wang Y, Patel SP and Rana TM: ALKBH5
regulates anti-PD-1 therapy response by modulating lactate and
suppressive immune cell accumulation in tumor microenvironment.
Proc Natl Acad Sci USA. 117:20159–20170. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Panneerdoss S, Eedunuri VK, Yadav P,
Timilsina S, Rajamanickam S, Viswanadhapalli S, Abdelfattah N,
Onyeagucha BC, Cui X, Lai Z, et al: Cross-talk among writers,
readers, and erasers of m6A regulates cancer growth and
progression. Sci Adv. 4:eaar82632018. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Mao S, Chen Z, Wu Y, Xiong H and Yuan X:
Crosstalk of eight types of RNA modification regulators defines
tumor microenvironments, cancer hallmarks, and prognosis of lung
adenocarcinoma. J Oncol. 2022:12856322022. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Qi L, Zhang W, Ren X, Xu R, Yang Z, Chen
R, Tu C and Li Z: Cross-talk of multiple types of RNA modification
regulators uncovers the tumor microenvironment and immune
infiltrates in soft tissue sarcoma. Front Immunol. 13:9212232022.
View Article : Google Scholar : PubMed/NCBI
|
